Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment

Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment

A comprehensive understanding of the dynamic changes in interleukin-6 (IL-6) levels is essential for monitoring and treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). By analyzing the correlations between IL-6 levels and health conditions, underlying diseas...

Full description

Bibliographic Details
Main Authors: Jian Wu, Jiawei Shen, Ying Han, Qinghua Qiao, Wei Dai, Bangshun He, Rongrong Pang, Jun Zhao, Tao Luo, Yanju Guo, Yang Yang, Qiuyue Wu, Weijun Jiang, Jing Zhang, Mingchao Zhang, Na Li, Weiwei Li, Xinyi Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID-19
IL6
tocilizumab
CPT
discharge
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.598799/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.598799/full

Similar Items